Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (July 21st Preview)
-
Precision oncology diagnostics consolidation
Tempus AI agreed to buy Personalis for $1.5 billion, stepping deeper into minimal residual disease (MRD) testing and expanding its tumor-informed liquid biopsy portfolio. Under the deal terms, Personalis shareholders will receive $16.25 per share, a ~6% premium to the closing price, with expected close in late 2026 or early 2027 subject to approvals. The acquisition builds on a commercial partnership dating to November 2023, when Tempus invested in Personalis and co-commercialized the NeXT Personal MRD test—a whole-genome sequencing-based, tumor-informed assay. Tempus said combining Personalis’ technology with its multimodal data platform and AI capabilities will support biomarker discovery and personalized cancer care. Personalis reported preliminary second-quarter revenue of $22.4 million and delivered 10,384 tests, both indicating accelerating commercial momentum alongside broader insurance coverage. Tempus expects the Personalis test to complement its existing tumor-naive MRD offerings, as the market shifts toward tumor-informed approaches.
-
AI infrastructure bets by Big Pharma
Bristol Myers Squibb and Nvidia said they will expand pharma’s AI compute footprint, targeting “the most powerful AI factory in life sciences.” BMS plans to build new infrastructure around an NVIDIA DGX SuperPOD system enabled with AIDGX Vera Rubin NVL72 systems, with BMS positioning it as an energy-efficient, single-owned Nvidia setup. The expansion follows a three-year Nvidia collaboration that initially deployed DGX SuperPOD for BMS R&D. BMS said the upgraded platform is intended to support a “hybrid intelligence” workflow—pairing AI co-scientists with human researchers to increase the likelihood programs advance on the right hypotheses. The announcement places BMS among multiple major pharma companies investing heavily in Nvidia partnerships and data-center scale computing as they pursue more automated discovery and operational efficiencies. BMS also cited other AI initiatives, including collaborations tied to Anthropic and Microsoft deployments in clinical-adjacent workflows.
-
Gene-editing in vector research
Researchers reported the world’s first gene-edited biting midges (Culicoides), opening a new path for studying how these vectors transmit livestock diseases. The advance targets Culicoides, small blood-feeding insects responsible for spreading bluetongue virus, Schmallenberg virus, and epizootic hemorrhagic disease virus—major drivers of losses in global livestock production. Because Culicoides are only 1–4 mm, the lab work has historically been difficult, limiting mechanistic studies of vector competence. The gene-editing capability described in the report is intended to make those studies tractable by enabling controlled experimentation on the biology of transmission. If the approach scales, it can support vaccine, surveillance, and vector-control strategies by pinpointing which genetic factors influence viral spread rather than relying on correlative studies alone.
-
Early signals of praziquantel resistance
A new whole-genome study identified early genomic indicators that Schistosoma mansoni may be developing reduced sensitivity to praziquantel, the sole widely used drug for schistosomiasis control. Published in Science Advances, the research analyzed 570 parasites collected across Africa and the Caribbean, led by investigators at the Wellcome Sanger Institute, the Royal Veterinary College, and the Medical College of Wisconsin. The team focused on variation in Sm.TRPM.pzQ, a transient receptor potential (TRP) melastatin ion channel recently linked to praziquantel’s molecular target. They found four naturally occurring receptor variants associated with reduced drug sensitivity and reported evidence of treatment failure via parasite infrapopulations sampled before and after praziquantel exposure. The authors framed the work as a shift from reactive to proactive monitoring, leveraging large-scale whole-genome sequencing to map how parasite populations are structured and evolving under mass drug administration (MDA).
-
Pan-cancer tumor organoid platform for precision testing
Researchers published a pan-cancer patient-derived organoid (PDO) platform designed for precision oncology modeling and therapeutic vulnerability screening. In Science Advances, the team described 220 PDOs generated from 191 patients across 15 cancer types, reporting high fidelity to parent tumors across histopathology, driver mutations, and gene expression signatures. The platform maintained stability over extended culture, with the study citing 93% histopathology concordance, 80% median genomic concordance for driver mutations, and a 0.85 median gene expression correlation. Clonality analyses indicated that most dominant tumor clones were preserved, supporting reproducible long-term preclinical testing. To demonstrate utility, the researchers tested a PARP inhibitor, talazoparib, in organoids from patients who had been deemed ineligible for PARP inhibitors by standard clinical criteria. They found that 58% of those organoids showed substantial sensitivity, suggesting current decision rules may exclude patients who could benefit.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.